High-Risk Neuroblastoma Treatment Review

被引：176

作者：

Smith, Valeria ^{[1
]}

Foster, Jennifer ^{[1
]}

机构：

[1] Baylor Coll Med, Texas Childrens Canc & Hematol Ctr, Dept Pediat, Houston, TX 77030 USA

来源：

CHILDREN-BASEL | 2018年 / 5卷 / 09期

关键词：

neuroblastoma; high-risk neuroblastoma; diagnosis; treatment; STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; STAGE; 4; NEUROBLASTOMA; RADIATION-THERAPY; 13-CIS-RETINOIC ACID; PHASE-3; TRIAL; CLASSIFICATION; RADIOTHERAPY; CRIZOTINIB; REMISSION;

D O I：

10.3390/children5090114

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Neuroblastoma is the most common extracranial solid tumor in children. One subset, high-risk neuroblastoma, is very difficult to treat and requires multi-modal therapy. Intensification of therapy has vastly improved survival rates, and research is focused on novel treatments to further improve survival rates. The current treatment schema is divided into three stages-induction, consolidation, and maintenance. This review serves as an overview of the current treatment for high-risk neuroblastoma and a glimpse at current research for future therapy.

引用

页数：7

共 38 条

[1] Efficacy of complete resection for high-risk neuroblastoma: A children's cancer group study [J].

Adkins, ES ;

Sawin, R ;

Gerbing, RB ;

London, WB ;

Matthay, KK ;

Haase, GM .

JOURNAL OF PEDIATRIC SURGERY, 2004, 39 (06) :931-936

[2] Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma [J].

Bassiri, Hamid ;

Benavides, Adriana ;

Haber, Michelle ;

Gilmour, Susan K. ;

Norris, Murray D. ;

Hogarty, Michael D. .

TRANSLATIONAL PEDIATRICS, 2015, 4 (03) :226-238

[3]

Brodeur G., 2016, PRINCIPLES PRACTICE, P772

[4] REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT [J].

BRODEUR, GM ;

PRITCHARD, J ;

BERTHOLD, F ;

CARLSEN, NLT ;

CASTEL, V ;

CASTLEBERRY, RP ;

DEBERNARDI, B ;

EVANS, AE ;

FAVROT, M ;

HEDBORG, F ;

KANEKO, M ;

KEMSHEAD, J ;

LAMPERT, F ;

LEE, REJ ;

LOOK, AT ;

PEARSON, ADJ ;

PHILIP, T ;

ROALD, B ;

SAWADA, T ;

SEEGER, RC ;

TSUCHIDA, Y ;

VOUTE, PA .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1466-1477

[5]

Casey DL, 2016, INT J RADIAT ONCOL, V96, P393, DOI 10.1016/j.ijrobp.2016.05.020

[6] Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission [J].

Cheung, Nai-Kong V. ;

Cheung, Irene Y. ;

Kushner, Brian H. ;

Ostrovnaya, Irina ;

Chamberlain, Elizabeth ;

Kramer, Kim ;

Modak, Shakeel .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) :3264-3270

[7] The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report [J].

Cohn, Susan L. ;

Pearson, Andrew D. J. ;

London, Wendy B. ;

Monclair, Tom ;

Ambros, Peter F. ;

Brodeur, Garrett M. ;

Faldum, Andreas ;

Hero, Barbara ;

Iehara, Tomoko ;

Machin, David ;

Mosseri, Veronique ;

Simon, Thorsten ;

Garaventa, Alberto ;

Castel, Victoria ;

Matthay, Katherine K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) :289-297

[8] Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients [J].

Depuydt, Pauline ;

Boeva, Valentina ;

Hocking, Toby D. ;

Cannoodt, Robrecht ;

Ambros, Inge M. ;

Ambros, Peter F. ;

Asgharzadeh, Shahab ;

Attiyeh, Edward F. ;

Combaret, Valerie ;

Defferrari, Raffaella ;

Fischer, Matthias ;

Hero, Barbara ;

Hogarty, Michael D. ;

Irwin, Meredith S. ;

Koster, Jan ;

Kreissman, Susan ;

Ladenstein, Ruth ;

Lapouble, Eve ;

Laureys, Genevieve ;

London, Wendy B. ;

Mazzocco, Katia ;

Nakagawara, Akira ;

Noguera, Rosa ;

Ohira, Miki ;

Park, Julie R. ;

Poetschger, Ulrike ;

Theissen, Jessica ;

Tonini, Gian Paolo ;

Valteau-Couanet, Dominique ;

Varesio, Luigi ;

Versteeg, Rogier ;

Speleman, Frank ;

Maris, John M. ;

Schleiermacher, Gudrun ;

De Preter, Katleen .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (10)

[9] Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers [J].

Elborai, Yasser ;

Hafez, Hanafy ;

Moussa, Emad A. ;

Hammad, Mahmoud ;

Hussein, Hany ;

Lehmann, Leslie ;

Elhaddad, Alaa .

PEDIATRIC TRANSPLANTATION, 2016, 20 (02) :284-289

[10] Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months [J].

Fischer, Janina ;

Pohl, Alexandra ;

Volland, Ruth ;

Hero, Barbara ;

Duebbers, Martin ;

Cernaianu, Grigore ;

Berthold, Frank ;

von Schweinitz, Dietrich ;

Simon, Thorsten .

BMC CANCER, 2017, 17

← 1 2 3 4 →